Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer: Patients more likely to stay on Lipitor than simvastatin

Pfizer: Patients more likely to stay on Lipitor than simvastatin

8th July 2008

Pfizer has announced the results of a large observational study showing that patients are more likely to stay on Lipitor (atorvastin alcium) than simvastatin.

The study of over 186,000 was published in the July issue of Current Medical Research and Opinion.

According to the results, patients who had no prior cardiovascular events were 15 per cent less likely to stop therapy in the first year than those taking simvastatin.

Furthermore, those who had experienced one prior cardiovascular event were 22 per cent less likely to discontinue treatment with Lipitor than simvastatin.

The results of a subanalysis of patients aged over 65 found similar results, with patients 22 per cent and 26 per cent less likely to stop treatment with Lipitor compared to simvastatin, depending on whether they had not experienced or had experienced a prior cardiovascular event respectively.

Dr Rochelle Chaiken, vice-president of the global cardiovascular and metabolic medical team at Pfizer, said: “Today, physicians face increasing pressure to switch from established statin therapy to generics, based on the perception that all statins are equivalent.”

She added that this study offers “real-world” insight into usage patterns for statin suggesting differences in patient compliance depending on the choice of statin.

Last month, Pfizer entered into an agreement with Ranbaxy Laboratories to settle the companies’ patent litigation regarding Lipitor worldwide.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.